Arbutus Biopharma Statistics Share Statistics Arbutus Biopharma has 191.7M
shares outstanding. The number of shares has increased by 1.16%
in one year.
Shares Outstanding 191.7M Shares Change (YoY) 1.16% Shares Change (QoQ) 0.09% Owned by Institutions (%) 47.18% Shares Floating 149.23M Failed to Deliver (FTD) Shares 8,167 FTD / Avg. Volume 0.76%
Short Selling Information The latest short interest is 11.16M, so 5.82% of the outstanding
shares have been sold short.
Short Interest 11.16M Short % of Shares Out 5.82% Short % of Float 8.27% Short Ratio (days to cover) 5.18
Valuation Ratios The PE ratio is -8.68 and the forward
PE ratio is -24.94.
Arbutus Biopharma's PEG ratio is
0.64.
PE Ratio -8.68 Forward PE -24.94 PS Ratio 98.35 Forward PS 430.6 PB Ratio 6.23 P/FCF Ratio -9.33 PEG Ratio 0.64
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Arbutus Biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.15,
with a Debt / Equity ratio of 0.01.
Current Ratio 8.15 Quick Ratio 8.15 Debt / Equity 0.01 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage -557.07
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $140.25K Profits Per Employee $-1.59M Employee Count 44 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 14.06% in the
last 52 weeks. The beta is 1.09, so Arbutus Biopharma's
price volatility has been higher than the market average.
Beta 1.09 52-Week Price Change 14.06% 50-Day Moving Average 3.89 200-Day Moving Average 3.45 Relative Strength Index (RSI) 54.53 Average Volume (20 Days) 1,069,782
Income Statement In the last 12 months, Arbutus Biopharma had revenue of 6.17M
and earned -69.92M
in profits. Earnings per share was -0.38.
Revenue 6.17M Gross Profit 4.79M Operating Income -76.32M Net Income -69.92M EBITDA -68.4M EBIT -69.78M Earnings Per Share (EPS) -0.38
Full Income Statement Balance Sheet The company has 36.33M in cash and 1.29M in
debt, giving a net cash position of 35.04M.
Cash & Cash Equivalents 36.33M Total Debt 1.29M Net Cash 35.04M Retained Earnings -1.35B Total Assets 103.27M Working Capital 98.1M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -64.85M
and capital expenditures -182K, giving a free cash flow of -65.03M.
Operating Cash Flow -64.85M Capital Expenditures -182K Free Cash Flow -65.03M FCF Per Share -0.35
Full Cash Flow Statement Margins Gross margin is 77.64%, with operating and profit margins of -1236.74% and -1133.04%.
Gross Margin 77.64% Operating Margin -1236.74% Pretax Margin -1133.04% Profit Margin -1133.04% EBITDA Margin -1108.46% EBIT Margin -1236.74% FCF Margin -1053.83%
Dividends & Yields ABUS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ABUS is $5,
which is 14.2% higher than the current price. The consensus rating is "Buy".
Price Target $5 Price Target Difference 14.2% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 4, 2010. It was a
backward
split with a ratio of 1:5.
Last Split Date Nov 4, 2010 Split Type backward Split Ratio 1:5
Scores Altman Z-Score 5.49 Piotroski F-Score 4
